Literature DB >> 2788613

Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432.

H Fukui1, Y Koishihara, M Nagamuta, Y Mizutani, A Uchida.   

Abstract

The streptococcal preparation OK-432 was tested for the ability to stimulate human spleen leukocytes (SPL) for generation of interleukin 6 (IL-6). When SPL were cultured with OK-432 for 24 h in serum-free T medium, the cell-free supernatant induced production of IgM in the SKW6.CL-4 and IgG in the CESS human B cell line, while no such activity was detected in unstimulated SPL culture. The activity was neutralized by treatment with antiserum directed against B cell stimulatory factor 2 (BSF-2). An optimum production of BSF-2 was observed when SPL were stimulated with 10 micrograms/ml of OK-432. The culture supernatant also induced proliferation of IL-6-dependent murine hybridoma MH-60.BSF2 (hybridoma growth factor; HGF). It is thus evident that the molecule produced by OK-432-activated human SPL is BSF-2/HGF/IL-6. These results indicate that the antitumor agent OK-432 stimulates human spleen cells to produce IL-6.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788613     DOI: 10.1016/0165-2478(89)90048-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

3.  The effects of a biological response modifier, OK-432, on tumor-induced alterations in the host metabolism.

Authors:  Y Noguchi; A Tsuburaya; T Makino; K Fukuzawa; K Nomura; T Yoshikawa; A Matsumoto; Y Moriya; K Masuda
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

4.  New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases.

Authors:  T Kanai; M Monden; M Sakon; M Gotoh; K Umeshita; Y Hasuike; H Nakano; T Monden; T Murakami; H Nakamura
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Use of a local immunotherapy as an adjunctive tool for the generation of human monoclonal antibodies from regional lymph nodes of colonic cancer patients.

Authors:  T Yagyu; T Monden; Y Tamaki; H Morimoto; T Takeda; T Kobayashi; T Shimano; H Murakami; T Mori
Journal:  Jpn J Cancer Res       Date:  1992-01

6.  The changing pattern of the splenic lymphocyte subsets in tumor-bearing mice after oral treatment with OK-432.

Authors:  Y Akamatsu; S Fuchimoto; K Orita
Journal:  Jpn J Cancer Res       Date:  1992-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.